

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability					Traceability																		
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}											
Set of samples 1																									
(81) Digoxin					12																				
Samples and groups		[nmol/L]																							
Sample A1		1,38	0,23	17	12																				
(4) LIA, ILMA		1,36	0,32	24	8	0					0		CRV	1,403	0,014	36%	0,897	1,91	12	12	100%				
Other					4	0																			

Sample B1		3,60	0,44	12	12																				
(4) LIA, ILMA		3,52	0,62	18	8	0								4x 6	CRV	3,551	0,036	36%	2,27	4,83	12	12	100%		
Other					4	0																			

(82) Theophylline					4																				
Samples and groups		[µmol/L]																							
Sample A1		48,6	4,5	9,3	4																				
Other					4	0																			

Sample B1		60,5	2,5	4,1	4																				
Other					4	0																			

(84) Phenobarbital					5																				
Samples and groups		[µmol/L]																							
Sample A1		59,9	6,2	10	5		CVP	57	2,2	20%	45,6	68,4	5	5	100%										
Other					5	0							5												

Sample B1		166	13	8,0	5		CVP	160	5,2	20%	128	192	5	5	100%										
Other					5	0							5												

(85) Phenytoin					4																				
Samples and groups		[µmol/L]																							
Sample A1		49,4	2,5	5,1	4		CVP	50,8	1,1	20%	40,6	61	4	4	100%										
Other					4	0							4												

Sample B1		60,4	3,3	5,4	4		CVP	61,4	1,3	20%	49,1	73,7	4	4	100%										
Other					4	0							4												

(86) Carbamazepin					9																				
Samples and groups		[µmol/L]																							
Sample A1		23,4	2,3	10	9		CVP	23,8	0,63	20%	19	28,6	9	8	89%										
Other					9	0							9												

Sample B1		16,7	2,1	13	9		CVP	17,2	0,51	20%	13,7	20,7	9	8	89%										

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: Slovakia, minimal size of groups n = 5

EQA round: TDM1/19 - Therapeutic Drugs

Dead line: 12.04.2019

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(86) Carbamazepin	[µmol/L]				9							9	8	89%									0
Samples and groups																							
Sample B1		16,7	2,1	13	9		CVP	17,2	0,51	20%	13,7	20,7	9	8	89%								0
Other					9	0							9										
							1x 1, 2x 2, 4x 4, 2x 6																
(88) Valproic acid	[µmol/L]				10								10	9	90%								0
Samples and groups																							
Sample A1		519	35	6,7	10		CVP	519	8,5	20%	415	623	10	10	100%								0
Other					10	0							10										
							1x 1, 1x 2, 4x 4, 4x 6																
Sample B1		241	24	10	10		CVP	239	4,6	20%	191	287	10	9	90%								0
Other					10	0							10										
							1x 1, 1x 2, 4x 4, 4x 6																
Set of samples 2																							
(89) Amicacin	[µmol/L]				1								1	0	0,00								0
Samples and groups																							
Sample A2		8,21			1		CVP	6,42	0,41	20%	5,13	7,71	1	0	0,00								0
Other					1	0							1										
							1x 2																
Sample B2		21,6			1		CVP	22,4	0,54	20%	17,9	26,9	1	1	100%								0
Other					1	0							1										
							1x 2																
(90) Gentamicin	[µmol/L]				7								7	6	86%								0
Samples and groups																							
Sample A2		31,6	6,5	20	7		CVP	28,3	1,7	31%	19,5	37,1	7	6	86%								0
Other					7	0							7										
							1x 1, 1x 2, 4x 4, 1x 6																
Sample B2		13,9	1,4	10	7		CVP	13,6	0,51	31%	9,38	17,9	7	7	100%								0
Other					7	0							7										
							1x 1, 1x 2, 4x 4, 1x 6																
(92) Vankomycin	[µmol/L]				9								9	9	100%								0
Samples and groups																							
Sample A2		31,2	0,82	2,6	9		CVP	31,4	1,1	28%	22,6	40,2	9	9	100%								0
(4) LIA, ILMA		31,2	0,82	2,6	5	0							5										
Other					4	0							4										
							1x 1, 1x 2, 1x 6, 1x 99																
Sample B2		21,3	0,57	2,7	9		CVP	21,8	0,82	28%	15,6	28	9	9	100%								0
(4) LIA, ILMA		21,3	0,57	2,7	5	0							5										
Other					4	0							4										
							1x 1, 1x 2, 1x 6, 1x 99																
(93) Methotrexate	[µmol/L]				2								2	1	50%								0
Samples and groups																							
Sample A2		0,503	0,03	7,4	2		CVP	0,568	0,049	30%	0,397	0,739	2	2	100%								0
Other					2	0							2										
							1x 2, 1x 4																
Sample B2		1,26	0,12	9,5	2		CVP	1,72	0,29	30%	1,2	2,24	2	1	50%								0
Other					2	0							2										
							1x 2, 1x 4																

